Why EVQLV? The Interesting Story Behind Our Name

Feb 19, 2020 | Blog | 0 comments

Daniel Gigante

Andrew Satz (CEO) and I had a conversation covering a question we hear quite a bit: how did we come up with the name EVQLV? It’s an interesting story that includes evolution, amino acids and startups. Enjoy!

Transcript of Conversation

Daniel: Andrew, how did you come up with the name EVQLV?

Andrew: We started working on evolutionary algorithms in 2019, and we always thought about the fact we were building things around evolution. Obviously, if you look around the internet, the word “evolution” or “evolve.com” are taken as company names. As we were developing our work, and we’re in the antibody space, and antibodies are comprised of amino acids. There are 20 common amino acids and they’re each represented by a letter of the alphabet, and the first five letters on the heavy chain of the amino acid sequence are E-V-Q-L-V.  We were like, wow, that’s very cool! It looks like the word “evolve.”

Some other things, we want to change the way people see life sciences and pharmaceuticals. So, making the “O” a “Q” was a nod to that goal. Interestingly enough, when I thought about how the logo would look, I thought we should make the line coming out of the Q a double helix…when we tried to make it, it looked really weird. EVQLV [the name] is also very startupy. You know, companies use a 3 instead of a B or a 4 instead of an A…it was really all of those things coming together and we agreed: this is an awesome name.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest